All Articles

Record home price cuts signal a major market shift. We go beyond the headlines to analyze if this is a healthy correction or a warning sign.

A hedge fund's 1.44% derivative stake in Dowlais Group reveals the complex financial strategies shaping the blockbuster American Axle merger.

Kellanova, Walmart, and Indigo Ag are paying farmers to go green. But is their new partnership a true blueprint for sustainable agriculture or just a drop in the bucket?

Chery Group's new EV brand, LEPAS, arrives in South Africa with premium ambitions. Can its 'elegance' philosophy overcome infrastructure hurdles and fierce competition?

A routine investment announcement offers a window into the economic pressures shaping household stability and the future of Canadian public services.

Activist investor Engaged Capital demands records from BlackLine's board over a rejected $4.5B SAP offer, setting the stage for a major proxy battle.

Manulife announced its estimated 2025 reinvested ETF capital gains. Learn what this "phantom income" means for your portfolio and your tax bill.

Manulife's estimated December ETF distributions are out, offering a crucial glimpse for income seekers planning for 2026 in a complex market.

RAID's blockbuster crossover with Alien and Predator isn't just fan service. It's a calculated strategy driving revenue and redefining player engagement.

With a leaner profile, BioLineRx bets on a novel glioblastoma drug while advancing its diverse pipeline. A deep dive into the strategy and the science.

Sarepta's clinical progress in myotonic dystrophy signals a major diversification beyond Duchenne, leveraging a high-stakes siRNA partnership.

Aldebaran Resources reveals a robust economic study for its Altar copper mine, but the news is eclipsed by a key partner's surprise withdrawal.

A Colorado cybersecurity firm's radical shift to a 32-hour week is boosting client satisfaction. Is this a new blueprint for high-stakes industries?

Quebec's new legal vape market is more than just products; it's a case study in building the regulatory infrastructure to tame a massive illicit trade.

Despite an FDA-approved product, Clearside Biomedical files for Chapter 11, putting its revolutionary eye-drug tech and a Phase 3 asset up for grabs.

After selling its first FDA-approved drug, Seres Therapeutics pivots to its next-gen candidate, SER-155, facing a make-or-break moment for its future.

With a $700M oversubscribed funding round, X-energy is attracting serious investors. Is this the moment advanced nuclear power finally goes mainstream?

While rivals bleed cash, Cannara Biotech posts record profits. We dissect its disciplined strategy of regional dominance and operational excellence.

A new deal between Renault and telematics leader Ituran is set to redefine vehicle security and connectivity for millions across Latin America.

A small firm's win in a U.S. Army contest reveals a radical new approach to rapidly deploying AI-powered defenses against the growing drone threat.